Quick Links
Contact us
Submit a medical question on an Otsuka product.
To discuss a medical inquiry on an Otsuka product, please call 1-800-441-67631-800-441-6763.
To report an adverse event or a product quality complaint, please call 1-800-438-99271-800-438-9927.
Featured news
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene.
Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS
Otsuka Pharmaceutical Development & Commercialization, Inc. today announced the initiation of a global early access program (EAP) for ulefnersen, an investigational antisense oligonucleotide, for eligible people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1, who have a confirmed genetic diagnosis and meet predefined program eligibility criteria.
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. today presented new results from the Phase 3b study (NCT06973577) evaluating centanafadine in adults with attention-deficit/hyperactivity disorder and comorbid anxiety disorders at Psych Congress 2026 in New Orleans.